Transforming Medicine
Through Technology
The Future of Medicine
Innovate
Tuesday • June 5, 2012 • 2:30 pm - 8:30 pm • Woodlake Hotel, Sacramento
WELCOME
Welcome to SARTA’s 2012 Med Tech Showcase. At MedStart, we envision a thriving medical device and bioscience
industry in our region, and our mission is to be a catalyst in making that happen. We believe in building on our
strengths and have identified three subsectors where ongoing research and development led by small but growing
and thriving networks of talented people, companies and institutions promise to transform medicine and healthcare
over time: Telehealth, Regenerative Medicine and Molecular Imaging. This year, we begin with three concurrent
sessions focused on these subsectors, which then feed into a plenary session and dinner. The plenary sessions
address needs common to all of med tech and bioscience, with sessions on the Future of Early-Stage Med Tech
Investing, Adoption of New Technologies by Health Systems, the Claire Pomeroy Award for Innovation, and our
Keynote Address. While the challenges facing new product development in med tech and bioscience are daunting,
the opportunity is enormous: to make healthcare safer, more effective, less costly and more accessible, through
technology, and to expand our robust bioscience industry sector, creating jobs and wealth for our region, at the
same time. Thank you for joining us and we hope that you too will find your unique way to assist in this transformative
process.
Cary Adams
CEO, MedFORCE Accelerator
Chair, SARTA’s MedStart Program
On behalf of SARTA, the region’s champion of innovation and entrepreneurship, welcome to the third annual
Sacramento Med Tech Showcase! We are pleased to organize our community’s largest annual medical technology
event, bringing together the hundred-plus medical device and medical information technology companies, along
with the regional ecosystem that supports them, to celebrate the industry’s successes and lay the foundation for
future opportunity.
SARTA exists to accelerate technology ventures in the greater capital area, where, by “technology” we mean any
company with intellectual property at the core of its competitive advantage in the marketplace. This ranges from
today’s focus on medical technology companies, to clean tech, software and IT, agricultural technology, and more.
Our active Board of Directors knows that when technology companies grow, they grow quickly, and the jobs they
add are often high-value, knowledge-based opportunities that provide strong employment opportunities in our region.
In support of that mission, in 2012 and beyond, SARTA has identified five focus areas that will spur the success
of our regional technology companies – including medical device and medical technology. We are working to:
• drive job growth in the highest-opportunity economic clusters;
• accelerate investment dollars into local companies;
• utilize the region’s strongest assets more effectively;
• foster a culture that embraces risk-takers; and, ultimately,
• create a vibrant technology community where innovation can thrive.
SARTA’s ongoing efforts have been bolstered by the emerging priorities of the Next Economy, the capital region’s
prosperity plan, in which SARTA is a partner. Next Economy will identify transformational strategies that will
define and then achieve our region’s next economy – and the technology sector (broadly defined) is a fundamental
foundation of almost all of the transformational strategies that have been identified. (You can find more information
about Next Economy at nexteconomycapitalregion.org)
None of this could happen, however, without the talent and engagement of the people who are committed to its
mission, and today’s Showcase reflects that involvement. SARTA’s staff, particularly MedStart’s Program Director
Laura Good; SARTA’s Board leadership, particularly Cary Adams, who chairs the MedStart program; the many
business leaders involved with the MedStart Advisory Committee which guides the direction of the program; our
sponsors who provide the financial underpinning; and the entire growing ecosystem around the technology
community – all are essential to accelerating technology ventures in the region.
We hope you enjoy the Med Tech Showcase! Make today a day to be inspired by the innovation and entrepreneurship
you’ll see here – and by the ways in which it will help make healthcare safer, more effective, and less costly,
through technology.
Meg Arnold
CEO, SARTA
2
PROGRAM AGENDA
1:00 pm – 2:45 pm
Room C
California Telemedicine and eHealth Center Presents:
Developing a Successful Telehealth Program
2:30 pm – 3:00 pm
Med Tech Showcase Opens: Registration & Networking
3:00 pm – 4:30 pm
Concurrent Technology Sessions
Room C
Telehealth: Changing Healthcare through Innovative Technologies
Room D
The Promise of Molecular Imaging
Room E
New Products and Processes Advancing Regenerative Cures
4:30 pm – 4:45 pm
NETWORKING BREAK
Room F
4:45 pm – 5:30 pm
The Future of Early-Stage Med Tech Investing Room C
5:30 pm – 6:10 pm
Room F
6:10 pm – 6:15 pm
RECEPTION
No Host Cocktails
Banquet Hall AB
DINNER BANQUET BEGINS
Dinner Sponsor Cornish & Carey Commercial Newmark Knight Frank
6:15 pm – 6:25 pm
CLAIRE POMEROY AWARD FOR INNOVATION IN MEDICAL TECHNoLOGY
6:25 pm – 6:50 pm
Dinner Served
6:50 pm – 7:40 pm
Adoption of New Technologies by Health Systems
Dignity Health, Kaiser Permanente, Sutter Health, UC Davis Health System
7:40 pm – 8:20 pm
Keynote Address Gregory Sorensen, M.D., CEO of Siemens Healthcare North America
8:20 pm – 8:30 pm
Closing Comments
Text your feedback about this event to 916-850-2094
or visit isuggest.com/sarta-medstart from your mobile device.
Conference Twitter Hashtag: #MedTechSac
3
KEYNOTE ADDRESS
Emerging Medical Technologies: A Vision of the Future of Healthcare
Our Keynote Address this year is by Gregory Sorensen, M.D., CEO of Siemens Healthcare North America and
until recently a member of the faculty at Harvard Medical School. A world renowned specialist in neuroradiology
with a desire to be at the intersection of health science and technology, Dr. Sorensen leads Siemens during a time
of tantalizing progress in molecular imaging and cellular therapeutics, holding enormous promise for improved
diagnosis and treatment of many of our deadliest and most debilitating diseases. While cost containment efforts
and health policy developments could make the adoption of new technologies more challenging, Dr. Sorensen will
share his thoughts on the direction forward for medicine and his company. His personal story and new leadership at
Siemens is a testimony that innovation is more vibrant than ever.
Following the keynote address, Dr. Gordon C. Hunt, Jr., will engage Dr. Sorensen in a dynamic conversation
focused on visions for the future of technology in medicine.
Gregory Sorensen, M.D.
Chief Executive Officer, Siemens Healthcare North America
Dr. Gregory Sorensen leads Siemens’ healthcare business across all of North America, the company’s
largest global market. To this leadership position, he brings a deep understanding of technology, the
biological basis of disease, the importance of measurable outcomes, and the environment of clinical
practice. Prior to his appointment at Siemens in July 2011, Dr. Sorensen served as Professor of
Radiology and Health Sciences & Technology at Harvard Medical School; faculty member of the
Harvard-MIT Division of Health Sciences and Technology; and Co-Director of the A.A. Martinos Center
for Biomedical Imaging at Massachusetts General Hospital, as well as a visiting professor of
neuroradiology at Oxford University. Leading up to his appointment with Siemens, Dr. Sorensen was a
practicing neuroradiologist and active researcher with significant experience in clinical care, clinical
trials, and translational research. In addition to his Medical Degree from Harvard Medical School, Dr.
Sorensen holds a B.S. in Biology and an M.S. in Computer Science.
Gordon C. Hunt, Jr., M.D., MBA
Senior Vice President and Chief Medical Officer, Sutter Health
Since becoming Chief Medical Officer more than 15 years ago, Dr. Gordon Hunt’s focus has included
the identification, implementation and diffusion of innovative patient safety and quality. Under his
leadership, Sutter Health was an early adopter of the eICU®. He has extensive experience in medical
group formation, developing hospital-physician partnerships, and the integration of hospitals,
multi-specialty medical groups, and IPAs. Dr. Hunt was previously President of Pulmonary, Infectious
Disease and Critical Care Consultants and Chief of Staff of Sutter Medical Center of Sacramento. Dr.
Hunt is board certified in Internal and Pulmonary Medicine.
5
ADOPTION OF TECHNOLoGIES
Adoption of New Technologies by Health Systems
One of the many challenges facing new medical devices and bioscience products is to sell them into increasingly
complex health systems, which themselves are being transformed by the Affordable Care Act. Selling new technologies
to health systems often involves different but coordinated approaches to multiple offices within the C-suite, each
of which faces a daily onslaught of challenges and priorities to make their current systems work, leaving limited
bandwidth to consider new technologies that could transform what they are currently doing. Our Sacramento
region is well-served by four strong nonprofit health systems competing for our patient populations and for payor
contracts. And while they compete vigorously, they also collaborate sometimes where appropriate for the good of
the community. We’re very pleased this year to present a distinguished panel of health system representatives,
each telling a different story about a new technology recently adopted by their health system, collaborating with
SARTA here today to help you, the start-up community, understand how these sales were accomplished. Moderating
this panel is Kelly O’Connor of Siemens Healthcare, who navigates this challenging terrain daily, as part of his job
as Regional Vice President.
Beyond Stem Cells...
The evolving role of extracellular matrix tissue bioscaffolds in cardiovascular repair and regeneration
W. Douglas Boyd, M.D., Professor of Surgery & Director of Robotics & Biosurgery, UC Davis Health System
Dr. Douglas Boyd is recognized for his pioneering work in cardiothoracic surgery and for his use of robotic-assisted surgical systems.
He specializes in minimally invasive cardiac and robotic-assisted heart surgery. He completed the world’s first closed-chest,
beating-heart coronary artery bypass surgery using a robotic system in 1999 and performed the first human extracellular matrix
xenograft implant for cardiovascular repair several years later. Prior to his appointment as a professor of surgery at UC Davis Health
System, Dr. Boyd served as chair of the Department of Cardiothoracic Surgery at the Cleveland Clinic in Florida. He is a graduate of
Carleton University and obtained his medical degree from the University of Ottawa.
Advances in the management of breast cancer using INTRABEAM technology
Gregory M. Graves, M.D., Regional Oncology Medical Director, Sutter Health Sacramento Sierra Region
Serving as the section chair of General Surgery and also as the Chair of the Department of Surgery at Sutter Medical Center, Sacramento,
Dr. Gregory Graves has had an active role in Medical Staff affairs. He has served as Medical Director of the Sutter Cancer Center
for the last four years, recently expanding his directorship to include the five hospitals of the Sacramento-Sierra Region for Sutter. In
addition to running a busy clinical practice in Surgical Oncology, Dr. Graves is involved in the training of senior Surgical Residents prior
to their entry into practice as part of his appointment as Assistant Clinical Professor of Surgery at UC Davis.
The use of the InTouch Medical Robots for telestroke and other telehealth applications
Cindy Holst, MHA, Chief Strategy Officer, Greater Sacramento-San Joaquin Service Area, Dignity Health
Cindy Holst is responsible for strategic planning, service development and marketing for eight hospitals and related healthcare
services. She has more than 25 years of experience in healthcare planning and marketing, involving hospitals, medical groups and
ambulatory services. Cindy completed an undergraduate degree in Communications at the University of the Pacific and holds a
Masters Degree in Healthcare Administration from the University of San Francisco.
Image Distribution in Kaiser Permanente Across Northern California and Beyond
Andrew S. Klonecke, M.D., Subchief for Nuclear Medicine, North Valley, Kaiser Permanente
Dr. Andrew Klonecke specializes in Nuclear Medicine at Kaiser Permanente in Sacramento. Prior to joining Kaiser, he was the
Chief of Staff for Family Physicians of Sacramento and served in the Air Force where he received two Commendation Medals and
the first Oak Leaf Cluster. He belongs to the Society of Nuclear Medicine and is involved in clinical research including radionuclide
imaging of possible breast cancers and the use of monoclonal antibodies for infection diagnosis. Dr. Klonecke has authored nine
medical journal articles and helps to sponsor a yearly symposium for nuclear medicine technologists. He has been named one of
Sacramento Magazine’s Top Doctors.
Moderator
Kelly O’Connor, Regional Vice President - San Francisco, Siemens Medical Solutions
Kelly O’Connor is charged with leading the Medical Imaging, Therapy and Imaging IT business for Siemens Medical Solutions in
Northern California, Northern Nevada, and Hawaii. Previously, he spent over twelve years in various leadership roles in healthcare
including sales, sales operations, and multichannel distribution. He has worked in multiple domestic geographic regions including the
Northeast, Southeast, and the Western United States. Kelly holds a B.A. from Creighton University, an M.S. in Biology (Genetics)
from the University of Nebraska at Omaha, and did his management education at Carnegie Mellon University - Tepper School
of Business.
7
MED TECH INVESTING
The Future of Early-Stage Med Tech Investing
The issue of access to capital for startup and early-stage medical device companies remains both critical and in flux. Changes in the
venture capital world and the recent passage of the JOBS Act with its provision for crowd-funding are among the issues affecting access
to early-stage risk capital in general. In addition, regulatory uncertainty about the FDA’s modifications to the medical device approval
process further shapes early stage investing in medical technology companies specifically. In this session, four leading venture capital
investors will share their perspectives on the changing investing landscape and provide guidance to companies seeking to navigate
their way across that landscape. Integrated into this session, two emerging regional companies–Accelerated Medical Diagnostics and
SynGen--will present themselves to the audience and to venture investors from Aphelion, Bay City Capital, Delphi Ventures, and QB3.
At this session, you’ll learn about these dynamic and growing companies with their different areas of focus, and hear their existing and
prospective investors assess the effectiveness of their pitches and the persuasiveness of the business models they’re pursuing.
Philip Coelho, President and CEO, SynGen, Inc.
Philip Coelho is an engineer/inventor educated at UC Davis. He has been awarded more than 30 US patents related to cell cryopreservation,
cryogenic robotics, cell selection, blood protein harvesting, and surgical hemostasis. Currently, Mr. Coelho is leading the development of new
devices that isolate and capture purified stem and progenitor cells resident within peripheral or placental/cord blood, bone marrow or adipose
tissue. In 2010, Mr. Coelho received SARTA’s Claire Pomeroy Award for Innovation in Medical Technology for his invention, the BioArchive
System by ThermoGenesis.
Douglas Crawford, PhD, Associate Director, QB3, and Managing Director, Mission Bay Capital
Dr. Douglas Crawford seeks to stimulate economic growth in California by promoting cross-discipline academic research and accelerating the
transfer of the resulting innovations to the market. Dr. Crawford created and manages the first incubator within the University of California, the
QB3 Garage@UCSF, QB3 Garage@Berkeley, QB3 Mission Bay Innovation Center, and the QB3 East Bay Innovation Center. Together these
incubators are home to 45 companies. Crawford is also a founder and managing director of Mission Bay Capital, an $11.3M seed-stage
venture fund that seeks to make pivotal early-stage investments in bioscience companies emerging from the University of California. Dr. Crawford
received his PhD in biochemistry from UC San Francisco.
William G. Gerber, M.D., Investment Partner, Bay City Capital
Dr. William Gerber has been with Bay City Capital since September 1999. Prior to that, he was President and Chief Executive Officer of Epoch
BioSciences, acquired by Nanogen in 2004. Before then, Dr. Gerber served as President and Chief Executive Officer of diaDexus LLC, and
Vice President and Chief Operating Officer of Onyx Pharmaceuticals, President of Chiron Diagnostics, and Senior Vice President and General
Manager of the PCR Division of Cetus Corporation. Dr. Gerber is a member of the board of directors of Aviir, Inc., Conatus Pharmaceuticals,
ITC, SynGen, Inc. and Vivaldi Biosciences. Dr. Gerber received his M.D. from UC San Francisco Medical Center.
Paul Henderson, PhD, Co-founder, Accelerated Medical Diagnostics, & Associate Professor, Department of Internal Medicine, UC Davis
Dr. Paul Henderson’s research focuses on the relationship between drug-DNA interactions and response of cancer patients to chemotherapy.
Preclinical success with the platinum-based treatment of lung and bladder cancer cells motivated the founding of Accelerated Medical
Diagnostics, which is sponsoring an ongoing clinical diagnostic feasibility study at the UC Davis Cancer Center in collaboration with Lawrence
Livermore National Laboratory, with the goal of developing and commercializing a test to predict which cancer patients will respond to
chemotherapy. Dr, Henderson holds a PhD in organic chemistry from Georgia Tech and was an NIH Postdoctoral Fellow at MIT in the Division
of Biological Engineering.
John Maroney, Managing Member, Delphi Ventures
John Maroney joined Delphi Ventures in 2003 and focuses on medical device and diagnostic investments. Prior to joining Delphi, he was
President, CEO and Chairman of EndoTex Interventional Systems, Inc., a development stage, venture backed, start-up company focused on
commercialization of carotid artery stents, which was acquired by Boston Scientific Corp. John has held a variety of senior management
positions including President and General Manager at EP Technologies, Inc., VP of Operations at Boston Scientific Corp, and VP of Operations
at Cardiovascular Imaging. John earned his B.S. in Mechanical Engineering from UC Davis, where he currently serves on the Advisory Board
for the School of BioMedical Engineering.
Ned Scheetz, CFA, Managing Director, Aphelion Capital
Ned Scheetz has been helping to build successful Healthcare companies for nearly 20 years. Prior to forming Aphelion Capital, LLC in 2005,
he was a partner and managing director with Piper Jaffray Ventures and a senior research analyst covering medical technology companies for
Janus Capital. Ned is an active board member of Aardvark, Aurora, Curant, and SurgiQuest; an advisory board member with the Center for
Medical Device Innovation; and on the business advisory board of The Epilepsy Therapy Development Project. He is a graduate of Colby
College, Duke University’s Fuqua School of Business, and was a post-graduate scholar at Oxford University.
Moderator: Vikram Janardhan, Chief Executive Officer, Insera Therapeutics
Vikram Janardhan co-founded Insera Therapeutics, Inc., a biotech company focused on solutions for the treatment of stroke. In less than three
years since inception, Insera Therapeutics has won an NSF innovation grant; a federal R&D grant from HHS; and recently won Frost and
Sullivan’s 2010 National Award for Product Innovation. Prior to this role, Vikram was the President of Global Energy Software, where his
leadership culminated in a very successful exit in 2007 with the sale of the company to a private equity firm. He trained at the Wharton Business
School’s Executive Education program and has an M.S. in Electrical Engineering from Rensselaer Polytechnic Institute, NY.
9
Presents:
Developing a Successful Telehealth Program
What are the keys to building, implementing and operating a
successful telehealth program? In this fast paced seminar
we will provide you with information on the steps necessary
to build a telehealth program. We will cover initial program
considerations, program design, business cases, getting
support for your project, technology decisions, performance
monitoring, and program operations. Our presenters have
implemented dozens of telehealth programs and have
extensive experience in all areas of program initiation,
planning, design, implementation, operation and evaluation.
This program will be filled with practical advice, tips, and
tools that will help you get your telehealth program off the
ground or to the next level.
Christine L. Martin, MBA, MT, PMP
Executive Director, California Telemedicine & eHealth Center
Christine Martin has 16 years experience developing,
operating, and providing assistance to telehealth
programs. She has been the Director of CTEC for
the last five years. She developed and implemented
the telemedicine program for California Department
of Corrections and Rehabilitation (CDCR) prison
system and managed the program for 11 years. She
managed the provision of over 75,000 telemedicine visits and the
development of a Sacramento based provider center for CDCR
telehealth clinicians. She has authored a number of publications on
telehealth development and program guides on telehealth, including the
CTEC Program Developer Guide.
Susan Ferrier, RN
Executive Director, Connecting to Care
Susan Ferrier has over 12 years experience in
eHealth and telemedicine, including Director of
eHealth for the Northern Sierra Rural Health
Network. She has worked with many rural
health clinics planning for and implementing
telehealth programs. Susan is experienced
in grant w r i t i n g , g r a n t administration, data collection, and budget development and monitoring.
She holds a B.S. in Nursing.
Mark Schweyer, RN
Director of Telemedicine Services, Eastern Plumas Health Care
Mark Schweyer has 22 years experience in a variety
of eHealth applications including telemedicine,
home monitoring and telephonic nursing advice.
He began the telemedicine program for East
Plumas Health Care, which currently has 5 sites,
and has experience in development, implementation
and operation of telehealth programs.
10
TELEHEALTH
Telehealth: Changing Healthcare through Innovative Technologies
Telehealth technologies are transforming the healthcare delivery system, providing new methods to provide
access to quality care in a cost effective manner. The momentum to deploy telehealth across the spectrum of
healthcare is growing. Telehealth is in center stage in many federal initiatives and California passed new expanded
telehealth legislation that became effective in January 2012. Technologies continue to evolve, becoming smarter,
more powerful, smaller and less expensive. How will telehealth influence and support accelerated innovation
in the coming years? A look at today’s landscape can provide some insight. This panel of experts will consider
today’s environment and their view of the future in a variety of areas including the clinical service environment; the
infrastructure, funding and support for development; the expansion of services by payors; and the view from the
technology sector. This panel includes leadership from Intel, UC Davis, Wellpoint / Anthem Blue Cross, the California
Healthcare Foundation and the California Telehealth Network.
Moderator: Christine Martin, Executive Director, California Telemedicine and eHealth Center
Mark Blatt, M.D., Worldwide Medical Director, Intel
Dr. Mark Blatt joined Intel in 2000 working in the New Business Group. He is currently Worldwide Medical Director,
Enterprise Solution Sales, in the Sales and Marketing Group. In this role he concentrates on how health information
technology (HIT) infrastructure can enable providers to deliver cost effective, quality care to all citizens. He has
a particular interest in integrated care delivery, mobile point of care, secure computing and the emergence of cloud
computing services. Previously Dr. Blatt was the Director for Healthcare Industry Solutions in Intel’s Digital Health Group.
Eric Brown, President and CEO, California Telehealth Network
Under Eric Brown’s guidance, the California Telehealth Network (CTN) has grown to become the largest FCC Rural
Health Care Pilot Program in the nation with over 400 sites enrolled. CTN is dedicated to health care designed to
connect medical sites in rural and medically underserved communities with the State’s major medical centers and
research institutions to improve clinical outcomes and reduce costs. Eric is a member of the grant team that successfully
developed and is implementing the $9M UC Davis/CTN eHealth Broadband Adoption grant which is providing over
60 hours of online training content to raise the level of understanding of health-related broadband applications.
Richard Gooch, Senior TeleMedicine Liaison, Wellpoint, Inc / Anthem Blue Cross
Before joining Wellpoint, Inc. / Anthem Blue Cross, Richard Gooch worked with Quest Communications selling Video
Conferencing Services, Frame Relay and T-1 to commercial accounts. In 1996, he joined Wellpoint to help develop
a TeleMedicine Program to increase patients’ access to care. Dedicated to improving the healthcare and health
outcomes for rural Californians, WellPoint’s Anthem Blue Cross partnered with the California Medical Risk Insurance
Board (MRMIB) to form and fund the Anthem Blue Cross Telehealth Program.
Margaret Laws, Director, Innovations for the Underserved, California Healthcare Foundation
Margaret Laws oversees the Foundation’s work to reduce barriers to efficient, affordable care for the underserved. She
also directs the CHCF Health Innovation Fund, a three-year, $10M program-related investment fund. She joined the
Foundation in 1998 after serving as staff to the state of California’s Managed Care Improvement Task Force. Margaret
holds a Master’s degree in Public Policy from Harvard University’s John F. Kennedy School of Government and an A.B.
in English Literature from Princeton University.
Thomas S. Nesbitt, M.D., M.P.H.,
Associate Vice Chancellor for Strategic Technologies and Alliances, UC Davis Health System
Dr. Thomas Nesbitt is responsible for advancing the UC Davis Health System’s excellence in telemedicine. Toward that
goal, he works closely with leaders throughout the state in developing partnerships with regional hospitals, clinics and
centers to expand access to quality health care and create a statewide broadband telehealth network. He also ensures
that faculty and staff excel at using innovative technologies to provide high-quality, state-of-the-art medical care. As
founding director of the Center for Health and Technology, Dr. Nesbitt oversees UC Davis’ telemedicine, distance learning
and medical informatics programs. A key focus of the center is assuring interaction among physicians, educators,
information technology and communications specialists, engineers and researchers.
11
REGENERATIVE MEDICINE
New Products and Processes Advancing Regenerative Cures
Regenerative medicine is on the forefront of medical research, and California’s dominant role in the field is
bolstered by the state’s $3B fund to support research conducted in the state. The Sacramento region holds a
strong position in regenerative medicine research, thanks to a cluster of local companies and the UC Davis Institute
for Regenerative Cures with the talented faculty and researchers engaged there. The emerging field is
creating the need for specialized tools and resources to support the research and, eventually, clinical treatment
processes. This session will focus on the overall pipeline of regenerative cures and related devices, diagnostics
and research equipment and supplies, with comments from researchers as well as those whose businesses
support the research efforts.
Kirt Braun, PhD, Head of Marketing, North America, Miltenyi Biotec Inc
Dr. Kirt Braun has over 12 years of experience in the biotechnology industry. During his tenure he has been responsible
for bringing innovative products to market, with the goal to accelerate basic cellular research. Prior to joining Miltenyi
Biotec he was a Global Product Manager at Molecular Probes, a business segment of Invitrogen. Dr. Braun received
his PhD from Washington State University, School of Molecular Biosciences. His research focused on the signaling
regulation of the retinoic acid receptor alpha during cellular differentiation.
Leon L. Hall, PhD, Director, Scientific Operations, In Vivo Pharmacology Service, The Jackson Laboratory
Dr. Leon Hall has worked in preclinical research for over 13 years. A molecular biologist by training, he has expertise in
human disease modeling. He previously held a faculty position at UC Davis School of Medicine where he researched
the feasibility of using non-viral gene therapy and adult stem cells to treat neurodegenerative disorders. Dr. Hall is the
Principal Investigator on a $3.8M CIRM grant focused on the development and characterization of models for stem cell
applications. Dr. Hall holds a B.S. joint degree in honors biology and psychology from the University of Guelph, Canada,
and M.Sc. and PhD degrees in molecular biology from the University of Leicester, England.
Jan Nolta, PhD, Executive Director, Stem Cell Program, UC Davis Health System
In addition to conducting groundbreaking research into human stem cells as one of the nation’s leading stem cell
researchers, Dr. Jan Nolta is responsible for overseeing the expansion of UC Davis’ exploration of regenerative
medicine. Dr. Nolta’s research is focused on developing new and better stem cell therapies for treating liver disease,
cardiac infarction, and peripheral vascular disease, among others. She received a B.S. from California State University,
Sacramento, took master’s classes at UC Davis and earned a PhD in molecular microbiology from the University of
Southern California.
Dr. Matthew Plunkett, Chief Financial Officer, California Institute for Regenerative Medicine
Dr. Matthew Plunkett’s responsibilities include budgeting, forecasting, financial compliance, board reporting, the
company loan award program, and operational aspects of the organization. Previously, he served as VP and CFO at
iPierian. Prior to joining iPierian, Dr. Plunkett spent nine years at Oppenheimer & Co. and its predecessor CIBC World
Markets, most recently as Managing Director where he lead the firm’s biotechnology investment banking practice for
the West Coast. His investment banking experience includes over 70 completed biopharmaceutical transactions.
Previously, Dr. Plunkett worked as a Research Scientist at Sunesis Pharmaceuticals and at Axys Advanced Technologies.
He received a PhD in Organic Chemistry from UC Berkeley.
Joshua A. Wood, PhD, MBA, Vice President of Clinical Operations, StemExpress
Dr. Joshua Wood has over 8 years of experience in stem cell research and development for the treatment of heart
disease, autoimmune and inflammatory diseases, and regenerative medicine. He has a doctorate in Cell and Molecular
Biology from the University of Nevada, Reno and held a post-doctoral fellowship at UC Davis. Prior to joining
StemExpress, Dr. Wood published 15 peer-reviewed articles and has 1 pending patent application.
Moderator: Cate Dyer, Founder and CEO, StemExpress
Cate Dyer has over 13 years experience in patient care and medical research. She worked with human dissections and
organ donations at Santa Barbara Cottage Hospital and while working for a prominent Bay Area human tissue provider
as a procurement specialist, she started her first company, managing corporate building contracts. In 2010, Cate struck
a balance between her natural business acumen and love of medicine by founding StemExpress, which has since
become the new high standard in human tissue, blood and cell procurement and isolation for top research universities,
labs and hospitals across the country. Cate has a B.A. in both Liberal Arts and Sociology.
13
MOLECULAR IMAGING
The Promise of Molecular Imaging
Molecular Imaging is defined as a way to see, define and track how molecules in the body function and change –
particularly in relation to disease – and use that information to improve patient care, according to the Society of
Nuclear Medicine in its 2007 plenary session. But Molecular Imaging (MI) is much more as it drives the
advance of both pre-clinical therapy testing and the most advanced clinical diagnostics of modern medicine. MI is
at the cross-section of imaging instrumentation (MRI, PET, Optical), biochemistry (imaging agents) and software
(pattern recognition, quantification and modeling). Almost all areas of medicine are positively influenced by MI from
neurology to oncology. The promise for novel drug development, the monitoring of cell therapy and non-invasive
diagnostics cannot be overstated. This session is a unique occasion to learn about the recent developments in
molecular imaging, why our region has a clear advantage nationally and how this represents an opportunity for
new ventures in Sacramento.
Bijan Bijan, M.D., Associate Professor of Diagnostic Radiology & Nuclear Medicine, UC Davis;
Diagnostic Medical Imaging, Sutter Medical Group, Sacramento
Dr. Bijan Bijan is a board certified radiologist with training in cross-sectional Body Imaging/MRI & Nonvascular Interventional Radiology. He has trained over 100 radiology residents, nuclear medicine residents and fellows. He is the course director of the UC Davis
Nuclear Medicine review course and the UC Davis PET Symposium. He is an Associate Professor of Diagnostic Radiology & Nuclear
Medicine at UC Davis Medical Center and practices Diagnostic Medical Imaging at Sutter Medical Group, Sacramento. In addition to
his medical doctorate, Dr. Bijan holds an MBA, an MPH and an MHA.
Simon Cherry, PhD,
Professor of Biomedical Engineering, and Director of the Center for Molecular and Genomic Imaging, UC Davis
Dr. Simon Cherry’s research interests center around in vivo molecular imaging systems, especially very high-resolution PET systems
for preclinical imaging, and the microPET scanner. Additional interests include Cerenkov luminescence imaging and multi-modality
imaging, and integrating PET MRI. Dr. Cherry is a founding member of the Society of Molecular Imaging and a fellow of the IEEE,
BMES and AIMBE. He received the Imaging Achievement Award from the Society for Molecular Imaging in 2011, is the author of
more than 170 peer-reviewed journal articles or book chapters in the field of biomedical imaging, and co-authored the textbook
Physics in Nuclear Medicine.
Benjamin Franc, M.D., Chair, Nuclear Medicine Division, Radiological Associates of Sacramento
Dr. Benjamin Franc chairs the Nuclear Medicine Division at Radiological Associates of Sacramento (RAS), a multi-specialty group that
serves the Sacramento region. He joined the UC San Francisco faculty after completing his MS in chemical engineering and a nuclear
medicine residency at Stanford. Dr. Franc built a laboratory investigating novel methods of imaging cancer enzyme activity and
peptides using PET and SPECT at UC San Francisco. This work involved design and synthesis of new molecular probes and method
development in quantitative imaging. Dr Franc co-founded Impact Corelab, Inc. in 2010. Corelab is an extension of RAS, and is an
imaging/medical service provider.
Dennis Mathews, PhD, Director, NSF Center for Biophotonics Science and Technology, UC Davis
In addition to his role as Director at CBST, Dr. Dennis Matthews is the Associate Director for Biomedical Technology for the
Integrated Cancer Center at UC Davis and a professor in the UC Davis Department of Neurological Surgery. He is credited for inventing
and developing x-ray wavelength lasers at Lawrence Livermore National Laboratory and is currently in charge of developing new
Biotechnology program opportunities there. He has more than 270 publications and 30 patents and is the co-editor of the Journal of
Biophotonics. Dr. Matthews is credited with raising more than $150M in grant funds, helping create 10 startup companies and in
directing R&D programs as large as $35M/year.
Ruth Tesar, CEO, Northern California PET Imaging Center
Ruth Tesar has been involved in Molecular Imaging since 1993. She is the CEO of Northern California PET Imaging Center; one of
the first free-standing PET centers established in the US and helped to establish the data to support many of the clinical indications
for PET. She was involved as an officer in the start up of PETNET Pharmaceuticals in 1996. She was involved in gaining insurance
coverage for PET by private payers and CMS. Ruth served as President of the Institute for Clinical PET in 1998 and was recently
elected to the PET Center of Excellence Board of Directors.
Moderator: Christian Renaudin, D.V.M, PhD, Managing Partner and CEO, The MarkeTech Group
Under Dr. Christian Renaudin’s leadership, The MarkeTech Group (TMTG) has become an international leader in med tech marketing
research with offices in the USA and France. Most projects conducted by the firm are multi-country studies (Americas, Europe and Asia)
and involve both qualitative and advanced quantitative research. TMTG clients include almost all global med tech players as well
as over 100 midsize and VC funded companies. Dr. Renaudin is often cited in the medical imaging press for both his past scientific
research and now his market knowledge. He holds a doctorate degree in veterinary medicine, a doctorate degree of science in
biomedical engineering and an executive MBA degree in marketing and international business.
15
VentureStart prepares high growth
technology startups in the Sacramento
region to be investor-ready for Angel and
VC financing by providing mentoring,
resources, and connections.
To learn more visit www.venturestart.org
CLAIRE POMEROY AWARD
2012 Winner to be
Announced at the
Med Tech Showcase
on June 5th
2012 Nominees
William L. Bargar, M.D. - Robodoc, a surgical robot used in hip replacement surgery
John M. Boone, PhD - Breast scans using computer tomography (CT) imaging
Paul Douglas Corl, PhD - PrimeWire, pressure measuring coronary guide wire from Volcano Corporation
Melvyn Harris, M.D. - Evena Risk Mitigation Platform
Paul Kelly, M.D., FACS - CellSaver which saves surgery patients’ blood
John P. McGahan, M.D. - Pioneer in the invention of radio frequency ablation (RFA) for cancer treatment
Brian M. Watwood, Wijit® Lever Driving and Braking System
2012 Awards Committee
Claire Pomeroy, M.D., MBA, Chief Executive Officer, UC Davis Health System, Vice Chancellor,
Human Health Sciences, Dean, School of Medicine, UC Davis
Cary M. Adams, JD, CEO, MedFORCE Accelerator
Kyriacos A. Athanasiou, PhD, P.E., Distinguished Professor, Chair, Department of Biomedical Engineering, UC Davis
Don Chigazola, Director, Medtronic CardioVascular
John Maroney, Managing Member, Delphi Ventures
John Mesic, M.D., Chief Medical Officer, Sutter Health Sacramento Sierra Region
Robert Medearis, Founder and Chairman Emeritus of Silicon Valley Bank
Christian Renaudin, D.V.M, PhD, Managing Partner and CEO, The MarkeTech Group
Warren Smith, PhD, Professor, Electrical & Electronic Engineering Department,
California State University, Sacramento
17
ABOUT SARTA
SARTA is the leading non-profit fueling the growth of technology companies in the
Sacramento region. We are the nexus that links technology leaders, entrepreneurs,
investors, service providers, community organizations, and educational institutions.
SARTA is making
things happen.
Join the movement.
SARTA’s ongoing efforts:
• Spur job growth in the highest opportunity industry sectors.
• Position the region for ongoing investment.
• Leverage the area’s strongest assets.
• Develop a culture of risk takers to start new companies.
• Create a community where innovation can thrive.
SARTA is a 501(c)3 non-profit focused on the nine county region of Butte, El Dorado,
Nevada, Placer, Sacramento, Solano, Sutter, Yolo and Yuba counties.
Designed to stimulate the development and success of early
stage clean technology companies and to build a regional
clean tech cluster through education, collaboration, and
partnering.
With the mission to stimulate a thriving regional medical
technology cluster, MedStart convenes, informs, supports,
and promotes the 100+ med tech companies in the region.
Monthly business seminars on critical success topics for
technology companies at all stages of growth and for the
service and advisory companies that support the technology
sector.
Empowering early stage technology startups through
mentoring, resources, and connections to accelerate the
growth of world-class companies in the Sacramento region.
Executive Roundtables
SARTA’s by invitation, peer-to-peer networking groups
supporting confidential discussions among C-level technology
executives.
A regional industry/university technology center that serves
as a catalyst to accelerate the growth of developing technology
companies
Visit us at www.sarta.org for more information on our programs.
MedStart Executive Leadership
Meg Arnold
CEO, SARTA
Meg Arnold became CEO of SARTA in November 2009, after being closely involved as a SARTA Board member since
2005. Prior to joining SARTA, Meg was with UC Davis supporting technology commercialization and entrepreneurship
on the campus, with both UC Davis InnovationAccess and UC Davis CONNECT, where she developed programs to
support campus-originated start-up companies, and participated in technology transfer licensing to new start-ups.
Meg has worked as a consultant to Drexel University as Director, Community Partnerships, and to Valley Vision,
as Senior Project Manager for the Green Capital Alliance. Meg has an MBA in Finance from the University of San
Francisco, and a B.A. in English from Cornell University.
Cary Adams
CEO, MedFORCE Accelerator
Cary Adams, Chair of SARTA’s MedStart Program, is CEO of the newly founded Almond Tree Capital and MedFORCE
Accelerator, which focus on providing seed funding and a New Playbook for early stage med tech investing. A former
healthcare lawyer and long-time angel investor, he is a member of SARTA’s board of directors and its past Chair.
He says that, “The most gratifying thing about MedStart is to regularly become aware of some new company,
person or resource that makes our region an even better place in which to grow our bioscience industry sector.
For those of us who choose to focus on these assets, they are abundant, rewarding, and offer great opportunity to
improve medicine and healthcare while creating jobs and wealth in our region.”
19
SPONSORS
Executive
Presenting
Platinum
Dinner
Gold
Silver
Bronze
Apptology • Auqeo! • BoardEvals • City of Rancho Cordova • City of Roseville • City of Sacramento
Cook CPA Group • DCA Partners • Endicott Communications • Halldin Public Relations • NUTEK
Riverview Media Photography • Sierra Health Foundation • Wavepoint Ventures
Advisory Committee Acknowledgement
SARTA wishes to thank and acknowledge the members of the MedStart Advisory Committee
for their contributions in steering the activities of the MedStart program:
Cary Adams, Linda Aldrich, Gil Alvarado, Peter Bernardoni, Ted Black, Barbara Boczar,
Kelly Brenk, Michael Castorino, Jerry Clark, Anthony Hill, Alyson Iwamura,
Jacob Jorgensen, Mark Kania, Gabriela Lee, Binda Mangat, Richard Marshall,
Christine Martin, Greg McParland, Evelyn Milani, Christian Renaudin, Diane Richards,
Michael Rizzo, Micah Runner, Christopher Russell, Rick Shunn, Warren Smith, Jim Steel,
Tod Stoltz, Ruth Tesar, Vasilios Voudouris, and Thomas Woods
Feedback is delivered anonymously
and privately to the management of SARTA.
SARTA 3801 Power Inn Road, Sacramento, CA 95826 • 916.231.0770 • www.sarta.org
20